Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Fresenius Obtains Reimbursement Approval for Removab in Belgium

Oct. 4 (Bloomberg) -- Fresenius Biotech said the Belgian Health Ministry added its trifunctional antibody Removab to the list of reimbursable medications as of Oct. 1. The use of Removab will be reimbursed if the eligible patients also fulfill defined additional clinical inclusion criteria, the company said in an e-mailed statement today.

Link to Company News:{FME GR <Equity> CN <GO>} Link to Company News:{FRE GR <Equity> CN <GO>}

To contact the editor responsible for this story: Mariajose Vera at

Please upgrade your Browser

Your browser is out-of-date. Please download one of these excellent browsers:

Chrome, Firefox, Safari, Opera or Internet Explorer.